Disarm Therapeutics
Molly has 15 years of experience in industry administration and finance. She brings to Disarm Therapeutics considerable expertise in office operations at early- and development-stage biotech companies. Prior to joining Disarm, Molly was the executive assistant and office manager for ImmusanT. Prior to that, she was responsible for office management for the neuroscience team at AstraZeneca, office and grants administration at Proteostasis Therapeutics, and administrative support at Tolerx.
Molly earned her BLA and MS in Nonprofit Management and Philanthropy from Bay Path University.
This person is not in any teams
This person is not in any offices
Disarm Therapeutics
Disarm Therapeutics is a biotechnology company that creates disease-modifying therapeutics for patients with axonal degeneration. Its drugs prevent the loss of axons and treat neurological diseases including multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies that enable patients to avail treatment for acutediseases of the central, ocular, and peripheral nervous systems.